- The aim is to “evaluate the efficacy of the drug in the study of patients with Alzheimer’s disease or mild cognitive impairment, who have brain swelling”.
- The study will be carried out at the Ribera Povisa hospital (Vigo), under the direction of neurologist José Ramón Lorenzo González.
The Ribera Salud Foundation and Pratia have signed a contract to set up the first clinical trial as a result of their strategic alliance, which will study early Alzheimer’s disease at the Ribera Povisa hospital (Vigo), under the direction of neurologist José Ramón Lorenzo González.
The clinical trial, entitled “Randomised, placebo-controlled, double-blind study of XPro1595 in patients with early Alzheimer’s disease with biomarkers of inflammation”, aims to recruit a minimum of 5 patients.
The aim of this trial is, as explained by the Ribera Salud Foundation, “to evaluate the efficacy of the drug in the study of patients with Alzheimer’s disease or mild cognitive impairment who have brain inflammation”. Some participants, they add, will take the study drug, while others will take the placebo.
During this period, specialists at Ribera Povisa Hospital will perform brain imaging (MRI) measurements, blood tests and cognitive tests on patients participating in the study. At the end, a 12-month open-label extension is offered in which all participants take the study drug.
The launch of this trial represents the achievement of the first milestone for the advancement of medical research and the benefit to the patient, which both the Ribera Salud Foundation and Pratia promote in this collaboration that also seeks to increase patient access to innovative therapies in three of the hospitals of the Ribera group: the University Hospitals of Vinalopó (Elche) and Torrejón (Madrid) and the Hospital Ribera Povisa (Vigo).
About Pratia
Pratia is a network of research centres with more than 90 centres in six European countries. Since 2012, they have driven more than 1,500 clinical trials, enabling access to innovative therapies for patients with different pathologies. Pratia Spain is an SMO (Site Management Organization) with more than 20 years of experience with clinical research teams in hospitals of the National Health System (NHS). It provides management and coordination services for sites conducting clinical trials and aims to ensure that these trials are conducted efficiently and comply with the necessary regulations.
About the Ribera Salud Foundation
The Ribera Salud Foundation was established in 2022 with the aim of contributing to improving people’s overall health, quality of life and well-being, while at the same time responding to the Ribera group’s social commitment to the current and future population. The Foundation’s aims include the desire to promote and encourage research and the Ribera Health Group’s model of preventive, predictive, participatory, personalised and population-based medicine. In addition, the Ribera Salud Foundation seeks to promote innovation and build a better future, giving citizens the necessary tools to improve their quality of life through efficient health management and health education.
Recent Comments